Premium
Development of a new canine osteosarcoma cell line
Author(s) -
Séguin B.,
Zwerdling T.,
McCallan J. L.,
DeCock H. E. V.,
Dewe L. L.,
Naydan D. K.,
Young A. E.,
Bannasch D. L.,
Foreman O.,
Kent M. S.
Publication year - 2006
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2006.00112.x
Subject(s) - osteonectin , cell culture , clone (java method) , vimentin , osteosarcoma , in vivo , biology , cell , loss of heterozygosity , osteocalcin , in vitro , pathology , alkaline phosphatase , cancer research , immunology , genetics , medicine , immunohistochemistry , enzyme , gene , biochemistry , allele
Establishing a canine osteosarcoma (OSA) cell line can be useful to develop in vivo and in vitro models of OSA. The goal of this study was to develop, characterize and authenticate a new canine OSA cell line and a clone. A cell line and a clone were developed with standard cell culture techniques from a naturally occurring OSA in a dog. The clonal cell line induced a tumour after injection in RAG 1‐deficient mouse. Histology was consistent with OSA. The original tumour from the dog and the tumour induced in the mouse were both reactive with vimentin and osteonectin (ON). The parent cell line and clonal cell line were reactive with ON, osteocalcin and alkaline phosphatase. Loss of heterozygosity was found in the same three microsatellite markers in the parent and clonal cell lines, and the tumour tissue grown in the mouse.